Takebayashi H, Oida H, Fujisawa K, Yamaguchi M, Hikida T, Fukumoto M, Narumiya S, Kakizuka A
Department of Pharmacology, Kyoto University Faculty of Medicine, Japan.
Cancer Res. 1996 Sep 15;56(18):4164-70.
We have created fusion proteins between Fas and the ligand-binding domain of the estrogen or retinoic acid receptor. Murine fibrosarcoma L929 cells and human cervical carcinoma HeLa cells expressing the fusion proteins demonstrated apoptotic phenotypes in a tightly estrogen- or retinoic acid-dependent manner in vitro. Moreover, the fusion protein-expressing L929 cells transplanted into nude mice were also killed through apoptosis after injection of an estrogen agonist. This represents a novel system, "cell targeting," that can eliminate cells not only in vitro but also in vivo through the activation of a natural suicide machinery, i.e., apoptosis, by currently used hormones. This system implies wide applications not only in developmental biology and neurobiology but also in medicine, especially for cancer gene therapy.
我们构建了Fas与雌激素或视黄酸受体的配体结合结构域之间的融合蛋白。表达这些融合蛋白的小鼠纤维肉瘤L929细胞和人宫颈癌HeLa细胞在体外呈现出严格依赖雌激素或视黄酸的凋亡表型。此外,将表达融合蛋白的L929细胞移植到裸鼠体内后,注射雌激素激动剂也可通过凋亡将其杀死。这代表了一种新型的“细胞靶向”系统,该系统不仅可以在体外,还能在体内通过激活天然的自杀机制(即凋亡),利用目前使用的激素来消除细胞。该系统不仅在发育生物学和神经生物学领域有广泛应用,在医学领域尤其是癌症基因治疗方面也有应用前景。